Abiogan

Abiogen Pharma is a leading Italian pharmaceutical company specializing in bone metabolism, osteoarticular diseases, and pain management. Headquartered in Pisa, the company was founded in 1997 by Massimo Di Martino, continuing a family legacy in the pharmaceutical industry that dates back to 1917. Abiogen is a leader in the development and commercialization of bisphosphonates, with a portfolio featuring key treatments such as alendronate and neridronate, the latter being a first-in-class therapy for rare conditions like osteogenesis imperfecta and complex regional pain syndrome (CRPS). Beyond its proprietary product line, which includes the widely used Vitamin D3 supplement Dibase, Abiogen operates a significant contract development and manufacturing organization (CDMO) and maintains a state-of-the-art GMP-certified production facility. The company is actively expanding its international footprint through strategic licensing and acquisitions, such as the 2023 purchase of EffRx Pharmaceuticals and a 2025 partnership with Ambros Therapeutics to bring neridronate to the North American market.